Clinical Trial Update: PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

View source ↗

Summary

This update describes an observational PMCF study of the PRESERFLO MicroShunt for primary open-angle glaucoma, with no control group and not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Open-angle Glaucoma

Drugs mentioned

• PreserFlo MicroShunt

Snippet

Sponsor: Santen SAS | Conditions: Primary Open Angle Glaucoma | Status: NOT_YET_RECRUITING